image
Healthcare - Biotechnology - NASDAQ - US
$ 3.35
0.601 %
$ 2.33 M
Market Cap
0.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RNAZ stock under the worst case scenario is HIDDEN Compared to the current market price of 3.35 USD, TransCode Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RNAZ stock under the base case scenario is HIDDEN Compared to the current market price of 3.35 USD, TransCode Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one RNAZ stock under the best case scenario is HIDDEN Compared to the current market price of 3.35 USD, TransCode Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
0 REVENUE
0.00%
-19.4 M OPERATING INCOME
-4.03%
-18.5 M NET INCOME
-5.59%
-18.1 M OPERATING CASH FLOW
-14.67%
-35.6 K INVESTING CASH FLOW
64.72%
15.9 M FINANCING CASH FLOW
265542.41%
0 REVENUE
0.00%
-2.17 M OPERATING INCOME
57.66%
-2.32 M NET INCOME
55.28%
-3.91 M OPERATING CASH FLOW
-67.22%
-12.9 K INVESTING CASH FLOW
-182.55%
2.45 M FINANCING CASH FLOW
211.62%
Balance Sheet TransCode Therapeutics, Inc.
image
Current Assets 4.46 M
Cash & Short-Term Investments 2.77 M
Receivables 0
Other Current Assets 1.69 M
Non-Current Assets 714 K
Long-Term Investments 0
PP&E 602 K
Other Non-Current Assets 112 K
Current Liabilities 3.49 M
Accounts Payable 0
Short-Term Debt 412 K
Other Current Liabilities 3.08 M
Non-Current Liabilities 38.3 K
Long-Term Debt 38.3 K
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall TransCode Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 517 K
Gross Profit -517 K
Operating Expenses 19.4 M
Operating Income -19.4 M
Other Expenses -872 K
Net Income -18.5 M
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-1130.30% ROE
-1130.30%
-358.75% ROA
-358.75%
-1183.47% ROIC
-1183.47%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis TransCode Therapeutics, Inc.
image
Net Income -18.5 M
Depreciation & Amortization 517 K
Capital Expenditures -35.6 K
Stock-Based Compensation 1.04 M
Change in Working Capital -1.08 M
Others -146 K
Free Cash Flow -18.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets TransCode Therapeutics, Inc.
image
RNAZ has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership TransCode Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 28, 2023
Bought 25.2 K USD
Fitzgerald Thomas A
Chief Financial Officer
+ 49350
0.51 USD
1 year ago
Sep 28, 2023
Bought 50 K USD
Dudley Robert Michael
Chief Executive Officer
+ 98000
0.51 USD
1 year ago
Jun 21, 2023
Bought 31.8 K USD
Dudley Robert Michael
Chief Executive Officer
+ 12000
2.6515 USD
1 year ago
Jun 20, 2023
Bought 16.8 K USD
Dudley Robert Michael
Chief Executive Officer
+ 6607
2.5498 USD
1 year ago
Jun 09, 2023
Bought 52.4 K USD
Dudley Robert Michael
Chief Executive Officer
+ 19000
2.76 USD
1 year ago
Jun 09, 2023
Bought 52.4 K USD
Dudley Robert Michael
Chief Executive Officer
+ 19000
2.76 USD
2 years ago
Sep 14, 2022
Bought 23 K USD
Dudley Robert Michael
Chief Executive Officer
+ 20000
1.15 USD
2 years ago
Jun 16, 2022
Bought 15.2 K USD
Fitzgerald Thomas A
Chief Financial Officer
+ 12000
1.27 USD
2 years ago
May 27, 2022
Bought 51.6 K USD
Dudley Robert Michael
Chief Executive Officer
+ 28000
1.8444 USD
7. News
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements TransCode shares to remain listed on Nasdaq BOSTON , Jan. 7, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with Listing Rules 5550(a)(2) and 5550(b)(1), the Exchange's minimum bid price and shareholders' equity rules, respectively. The Company has also resolved the violation regarding Listing Rule 5635 (the "Shareholder Approval Rule") by obtaining shareholder ratification of a July 2024 equity transaction. prnewswire.com - 1 week ago
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients currently being evaluated for eligibility in Cohort 3 PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results BOSTON , Dec. 18, 2024 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the Safety Review Committee (SRC) monitoring its Phase 1 clinical trial has unanimously approved opening of the third cohort of patients based on its favorable review of Cohort 2 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA critical to the emergence and progression of many metastatic cancers. prnewswire.com - 1 month ago
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split. globenewswire.com - 1 month ago
TransCode Therapeutics, Inc. Announces $8 Million Private Placement BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8 million before deducting fees to the placement agent and other offering expenses payable by the Company. globenewswire.com - 1 month ago
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from The Nasdaq Stock Market LLC (Nasdaq) that the Nasdaq Hearings Panel before which TransCode appeared on October 1, 2024, has determined to grant TransCode's request to continue its listing on The Nasdaq Stock Market subject to certain conditions to regain compliance. The Panel has also issued a Public Reprimand Letter in accordance with Listing Rule 5815(c)(1)(D). globenewswire.com - 2 months ago
TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate Two patients dosed; several additional patients screened for enrollment Trial to evaluate safety and tolerability of TTX-MC138 in patients with metastatic cancer TTX-MC138 is an antisense oligonucleotide conjugated to TransCode's proprietary TTX delivery system designed to inhibit microRNA-10b, a known driver of metastasis in multiple cancers Phase 1 clinical trial follows evidence of delivery and pharmacodynamic activity in prior first-in-human Phase 0 clinical trial with radiolabeled TTX-MC138 BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced dosing of the first two patients in its Phase 1 clinical trial with its lead candidate, TTX-MC138. globenewswire.com - 4 months ago
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded a $2 million Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support clinical evaluation of TTX-MC138, TransCode's lead therapeutic candidate. globenewswire.com - 4 months ago
TransCode Therapeutics, Inc. Announces Closing of Public Offering Boston, MA — July 24, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed to globenewswire.com - 5 months ago
Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today? TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares. TransCode Therapeutics is selling 10 million shares of its common stock for 30 cents each. investorplace.com - 5 months ago
TransCode Therapeutics, Inc. Announces Pricing of Public Offering Boston, MA — July 22, 2024 — TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t globenewswire.com - 5 months ago
TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Boston, MA – July 22, 2024 – TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), a clinical-stage RNA oncology company committed t globenewswire.com - 5 months ago
Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock Market LLC (Nasdaq) that the Company has regained compliance with all applicable Nasdaq listing standards. As a result, the Company's stock will remain listed and traded on the Nasdaq Stock Market. globenewswire.com - 7 months ago
8. Profile Summary

TransCode Therapeutics, Inc. RNAZ

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 2.33 M
Dividend Yield 0.00%
Description TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Contact 6 Liberty Square, Boston, MA, 02109 https://www.transcodetherapeutics.com
IPO Date July 8, 2021
Employees 10
Officers Mr. Thomas A. Fitzgerald M.B.A. Interim Chief Executive Officer, Chief Financial Officer, President, Vice President of Administration & Director Ms. Susan Duggan M.B.A., R.N. Senior Vice President of Operations Dr. Zdravka Medarova Ph.D. Co-Founder & Chief Scientific Officer Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board Dr. Daniel R. Vlock M.D. Chief Medical Officer Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor & Member of Scientific Advisory Board